Salute e Benessere

Financière de Tubize - Annual report 2023

FINANCIERE DE TUBIZE SA/NVAllée de la Recherche 60, 1070 BrusselsContact:investorrelations@financiere-tubize.be Annual Report 2023 Regulated information 16 March 2024 The board of directors of Financière de Tubize has established the 2023 annual report. This report is available on the websitewww.financiere-tubize.beProfit for the financial year: € 88.2 million (€ 85.2 million in 2022, +3,5%),Increase of outstanding bank borrowings from € 47.8 million at 31 December...
Nasdaq GlobeNewswire
16/03/2024

Sanofi: Information concerning the total number of voting rights and shares -…

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of theCode de commerce(the French Commercial Code) and article 223-16 of theRèglement général de l'Autorité des Marchés Financiers(Regulation of the French stock market authority) Sanofi a Frenchsociété anonymewith a registered share capital of 2,529,599,938 € Registered office : 46, avenue de la Grande Armée - 75017 Paris - France Registered at the Paris...
Nasdaq GlobeNewswire
15/03/2024

Bioretec Ltd's Annual Report and Financial Statements 2023 published

Further enquiries Further enquiries Timo Lehtonen, CEO, +358 50 433 8493Johanna Salko, CFO, +358 40 754 8172 Certified adviser Nordic Certified Adviser AB, +46 70 551 67 29 Bioretec in brief Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate...
PR Newswire
15/03/2024

Monoclonal Antibody (mABs) Therapeutics Market Worth $497.5 billion |…

Browse in-depth TOC on "Monoclonal Antibody (mABs) Therapeutics Market"365 - Tables58 - Figures350 - Pages Browse in-depth TOC on "Monoclonal Antibody (mABs) Therapeutics Market" 365 - Tables 58 - Figures 350 - Pages Monoclonal Antibody (mABs) Therapeutics Market Scope: The In-Vitro accounted for the largest share of production method in the monoclonal antibody therapeutics market in 2023. By Production Method, the monoclonal antibody therapeutics market is segmented into...
PR Newswire
15/03/2024

Redefining and Developing New Opportunities for Luxury Marketing: XIAOHONGSHU…

In today's dynamic market landscape, the profiles and purchasing behaviors of Chinese luxury consumers are evolving. The youth demographic is emerging as a significant force in the luxury market, utilizing high-end products as mediums for self-expression and individuality. At the same time, trends within the wider consumer base are evolving alongside shifts in their socio-economic profiles, prompting a push towards increased specialization and diversification. The emergence of these new trends…
PR Newswire
15/03/2024

Genmab Announces Initiation of Share Buy-Back Program

Company Announcement Repurchase of up to DKK 3.5 billion worth of sharesCompletion expected no later than December 16, 2024COPENHAGEN, Denmark; March 15, 2024 –Genmab A/S(Nasdaq: GMAB) announced today that it is initiating a share buy-back program. The share buy-back program will be undertaken on the terms set out below and in accordance with Regulation (EU) No. 596/2014 ('MAR') and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour...
Nasdaq GlobeNewswire
15/03/2024

X-Ray Detectors Market Worth $4.2 billion | MarketsandMarkets™

Browse in-depth TOC on "X-Ray Detectors Market" Browse in-depth TOC on "X-Ray Detectors Market" 215 - Tables38 - Figures217 - Pages X-Ray Detectors Market Scope: The Flat-panel detectors segment is to register significant growth rate over the forecast period of 2023-2029. Based on the technology, the global X-Ray Detectors Market is categorized based on technology, including Flat Panel Detectors, Computed Radiography Detectors, Line-Scan Detectors, and Charged...
PR Newswire
15/03/2024

SOPHiA GENETICS and The French Kidney Cancer Research Network (UroCCR) Publish…

UroCCR is one of the world's largest collaborative kidney cancer networks with 51 multidisciplinary clinical teams across France. In close relationship with the French Association of Urology (AFU), the goal of UroCCR is to connect a national, multidisciplinary network of medical and scientific professionals who focus on therapeutic management and applied research into kidney cancer. In 2021, UroCCR partnered with SOPHiA GENETICS to develop an AI-based model to predict whether kidney cancer will…
PR Newswire
15/03/2024

Notice of Annual General Meeting of Orexo

Shareholders who wish to participate in the meeting must be recorded in the share register maintained by Euroclear Sweden AB on Thursday 18 April 2024, and notify Orexo of their intention to attend the meeting not later than on Monday 22 April 2024 by post to Orexo AB, P.O. Box 303, SE-751 05 Uppsala, Sweden, by telephone +46 (0) 18 780 88 00, by telefax +46 (0) 18 780 88 88, or by e-mail to lena.wange@orexo.com. Shareholders who wish to participate in the meeting must be recorded in the…
PR Newswire
15/03/2024

2023 Novo Holdings Bioindustrial Investments Team Annual Review/Business Update

Anders Spohr, Senior Partner, Head of Bioindustrial Investments, said: "With the establishment of our dedicated investment team, Novo Holdings is more focused than ever on the bioindustrial sector, and our portfolio now comprises 23 companies, ranging from industry giants like Novozymes and Chr. Hansen to dynamic startups. These companies are pioneering the use of microorganisms and fungi to create sustainable substitutes such as biofuels, biomaterials, and chemical alternatives. Anders...
PR Newswire
15/03/2024

Novo Nordisk Foundation: The revolution began at a local pub: now, the human…

Professors Sir David Klenerman and Sir Shankar Balasubramanian at the University of Cambridge co-invented a technology that has revolutionised our fundamental understanding of life by enabling fast, accurate, large-scale genome sequencing. Professors SirDavid Klenermanand Sir Shankar Balasubramanian at theUniversity of Cambridgeco-invented a technology that has revolutionised our fundamental understanding of life by enabling fast, accurate, large-scale genome sequencing. In 2000, one...
PR Newswire
15/03/2024

Mendus' major shareholders and members of the Board of Directors and Management…

Press Release Stockholm, Sweden, March 15, 2024Mendus AB (“Mendus” or the “Company”) has received written declarations of intent whereby the Company's major shareholders, holding approximately 65.8 percent of shares in the Company, declare their intention to exercise warrants of series TO3 (the “Warrants”) to subscribe for newly issued shares corresponding to their holdings of Warrants during the subscription period 15-29 March 2024 at the subscription price of 0.48 SEK per share...
Nasdaq GlobeNewswire
15/03/2024

ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis

36,000 people across 17 markets responded to the company's fourth annual survey. 40% of respondents get no more than three nights of good sleep per week.More than one-third of respondents are now actively tracking their sleep patterns, and many are adjusting bedtime routines in an effort to improve sleep quality.SAN DIEGO, March15, 2024(GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the global leader in digital health and cloud-connected medical devices that transform...
Nasdaq GlobeNewswire
15/03/2024

The exercise period for warrants of series TO3 commences today

Press Release Stockholm, Sweden, March 15, 2024On June 8, 2023, Mendus AB (publ) (“Mendus” or the “Company”), (NASDAQ Stockholm: IMMU), announced that the Board of Directors had resolved on a capital raise of approximately SEK 317 million (the “Transaction”), comprised of a directed issue of shares and warrants to Flerie Invest AB of approximately SEK 90 million (the “Directed Issue”), in combination with a fully secured rights issue of units of approximately SEK 227 million (the...
Nasdaq GlobeNewswire
15/03/2024

ONWARD® Medical Reaffirms Guidance, Shares 2024 Strategic Priorities, and…

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)Company expects to commercialize its ARC-EX ®System and commence the Empower BP Pivotal Study for the ARC-IM ®System in 2024Company ended2023 with EUR 29.8M in cash; Q4 cash burn was EUR 7M; cash runway guidance reaffirmed through year-end 2024 Company reaffirms guidance and is highly confident the FDA submission for its...
Nasdaq GlobeNewswire
15/03/2024

Qilu Pharmaceutical Showcases QL1706 Clinical Trial Outcomes in Oral…

Cervical cancer is one of the most prevalent malignancies among women and a leading cause of cancer-related death. For those who have failed the first-line standard therapy, the currently available treatment options are inadequate. The objective response rate (ORR) for pembrolizumab was 12.2%, with an ORR of 0% in the PD-L1-negative population[1]. Additionally, the median progression-free survival (PFS) and median overall survival (OS) were reported to be 2.1 months and 9.4 months, respectively…
PR Newswire
15/03/2024

Vivoryon Therapeutics N.V. Announces Changes to Board Composition

Vivoryon Therapeutics N.V. Announces Changes to Board Composition Halle (Saale) / Munich, Germany, March 15, 2024– Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced changes among the Non-Executive members of its Board of Directors.Professor Morten Asser Karsdal, MSc,...
Nasdaq GlobeNewswire
15/03/2024

Seegene and Springer Nature Announce Awardees for the Open Innovation Program

During the initial stage of document screening, a total of 281 applications were submitted from 47 different countries, demonstrating worldwide interest in the program. Two rounds of evaluations, which included document assessment and on-site evaluations specific to each country were conducted. Following the rigorous assessment process, a total of 26 applications were selected. The total number of selected awardees is 17, including those who applied for more than one project. During the...
PR Newswire
15/03/2024

Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of…

Each Unit is comprised of one common share of the Company (a "Common Share") and one common share purchase warrant of the Company (a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share at an exercise price of $0.32 for a period of four (4) years from the date of issuance. Each Unit is comprised of one common share of the Company (a " Common Share ") and one common share purchase warrant of the Company (a " Warrant "). Each…
PR Newswire
15/03/2024

Syngene biologics manufacturing facility to be operational for US and European…

The facility will be available for biotech and pharma customers seeking drug substance and drug product contract manufacturing. The drug substance capacity includes two production suites with five 2KL single use bioreactors each, for a total capacity of 20KL. The facility also includes two high-speed vial filling lines capable of producing up to 1 million vials per day ranging from 1 to 100mL fill volumes. In addition to the production capacity, the site has a development suite for clinical…
PR Newswire
14/03/2024

Full-year 2024 guidance suspended due to the temporary pause of API production…

Press Release Paris – March 14 th, 2024– EUROAPI today announces that its Italian subsidiary, EUROAPI Italy S.R.L., is suspending the production of all APIs 1in Brindisi. Following an internal audit, quality control deficiencies due to potential local misconduct have been identified and are being further investigated. Production will remain suspended until further notice. The relevant health authorities have been informed. The company has initiated a...
Nasdaq GlobeNewswire
14/03/2024

Fagron publishes annual report 2023

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 14 March 2024 – 6:30 PM CET Fagron publishes annual report 2023 Fagron, the leading global player in pharmaceutical compounding, today publishes its annual report 2023. Discussion of the annual report and the approval of the financial statements will be put on the agenda of the annual general meeting of shareholders scheduled for 13 May 2024.The annual report is available in the official Dutch version and in English...
Nasdaq GlobeNewswire
14/03/2024

Zeus Names New Chief Executive Officer

Before that, he held various leadership positions within BD, where he developed an extensive and consistent track record of delivering durable, sustainable growth while creating a winning culture. From 2001-2016, he held a series of ascending management positions within Bard until BD acquired the company in December 2017. Before that, he held various leadership positions within BD, where he developed an extensive and consistent track record of delivering durable, sustainable growth while...
PR Newswire
14/03/2024

Report from Extraordinary General Meeting of Minesto AB

Approval of the Board of Directors' resolution on a new issue of units with preferential rights for existing shareholders Approval of the Board of Directors' resolution on a new issue of units with preferential rights for existing shareholders The Extraordinary General Meeting resolved to approve the Board of Directors' resolution from26 February 2024on a new issue of so-called units, consisting of shares and warrants of series TO4, with preferential rights for existing shareholders...
PR Newswire
14/03/2024
Altri  Comunicati